USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CARMOT THERAPEUTICS, INC.
Address:
409 ILLINOIS ST
SAN FRANCISCO, CA
Phone:
N/A
URL:
N/A
EIN:
126187268
DUNS:
828863022
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,140,641.00 3
SBIR Phase II $1,911,764.00 1

Award List:

Discovery of small molecule drug candidates that disrupt the NEMO/IKK signaling c

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$299,307.00
Agency:
HHS
Principal Investigator:
Stig K. Hansen
Abstract:
DESCRIPTION (provided by applicant): Protein-protein interactions represent the largest untapped opportunity for therapeutic development. The number of protein-protein interactions in human cells has been estimated to exceed 100,000, well above the ~30,000 human genes. This multitude of… More

A novel approach to discover selective small molecule inhibitors of FABP4 and FAB

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$299,807.00
Agency:
HHS
Principal Investigator:
Daniel A. Erlanson – 415-978-2159
Abstract:
DESCRIPTION (provided by applicant): A novel approach to discover selective small molecule inhibitors of FABP4 and FABP5 for the treatment of metabolic diseases The Western diet and lifestyle has brought an epidemic of health problems collectively referredto as metabolic syndrome. Obesity plays a… More

Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$541,527.00
Agency:
HHS
Principal Investigator:
Johan K. Enquist – 415-978-2176
Abstract:
DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the most challenging health problems of the 21st century. Global health care expenditures to treat diabetes and its complications are estimated to have been 376 billion in 2010, of which 198 billion was spent in the United… More

Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,911,764.00
Agency:
HHS
Principal Investigator:
Stig K. Hansen – 415-978-2176
Abstract:
DESCRIPTION: Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of cancer Project Summary/Abstract Protein-protein interactions represent the largest untapped opportunity for therapeutic development, but the field has languisheddue to lack of efficient lead finding… More